<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> or mixed vascular <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) appear to be much more common in elderly patients than AD alone </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) and AD are more prevalent in elderly patients receiving haemodialysis (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), leading to a loss of independence and a poor quality of life </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0520541" disease_type="Disease or Syndrome" abbrv="">Hypotensive episodes</z:e> in patients receiving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> contribute to vascular changes in the brain, with consequent progression of VaD and AD </plain></SENT>
<SENT sid="3" pm="."><plain>The use of the lowest individually optimized bolus dose of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, with fewer <z:e sem="disease" ids="C0520541" disease_type="Disease or Syndrome" abbrv="">hypotensive episodes</z:e> during and between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> procedures, may exert a sparing effect on changes in microvascular circulation and decrease the incidence of VaD and AD </plain></SENT>
<SENT sid="4" pm="."><plain>We believe that long-term use of LMWH, with its direct effect on amyloid β protein (Aβ) in the blood and on Aβ accumulation in the brain and indirect effects on prevention of complement activation, may delay the progression of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> in patients receiving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>There is a need for a robustly designed, prospective trial to evaluate the effects of long-term treatment with LMWH on mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo>, VaD and AD in elderly patients receiving maintenance <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
</text></document>